Biologic

Due to medical advancements, researchers are calling for an update to the U.S. Department of Defense’s policies restricting individuals with psoriasis and atopic dermatitis from joining and remaining in the military, according to a study.

DESTIN, Fla. — When choosing between biologic drugs for systemic lupus erythematosus, it is important to know the “ideal patient profile” each is best suited for, according to a speaker at the Congress of Clinical Rheumatology East.

The medical community recognizes World Asthma Day on the first Tuesday of each May to spotlight the progress made in asthma care and the challenges that remain.

If you see more than a few patients with inflammatory bowel disease, you likely already have been asked by a third-party payer to switch a patient’s adalimumab prescription from the reference product to a biosimilar.

The age of biosimilars has come for gastroenterology. This includes interchangeable products, three of which are now on the market. How this will impact patient care in the near and distant future is the subject of much speculation.

WASHINGTON — Physicians have a variety of safe and effective biologic choices for treating children with asthma, according to a presentation at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Induction and maintenance treatment with infliximab was more efficacious than vedolizumab in patients with Crohn’s disease, while efficacy was similar between the two therapies in patients with ulcerative colitis, according to data.

According to published results, patients who underwent arthroscopic rotator cuff repair with vs. without bone marrow stimulation had similar rates of healing, postoperative clinical outcome scores and range of motion.

WASHINGTON — Allergic status did not impact annualized asthma exacerbation rate reductions seen with mepolizumab, benralizumab and tezepelumab in patients with moderate to severe, uncontrolled asthma, according to study results.

Patients with plaque psoriasis that have lower baseline blood monocyte counts may respond to secukinumab therapy earlier than patients with higher counts, according to a study.